Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 107

Sort by

Sort Order Select

Journal Articles

The Tetraspanin CD53 Regulates Early B Cell Development By Promoting IL-7R Signaling

Zev J. Greenberg, BS, Darlene A. Monlish, PhD, Rachel L. Bartnett, Jeffrey J. Bednarski, MD PhD, Laura G. Schuettpelz, MD PhD

Blood (2019) 134 (Supplement_1): 79.

https://doi.org/10.1182/blood-2019-131641

Published: 2019

Journal Articles

AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia

Greta De Jong, Sophie E Levie, Remko Schotte, PhD, Wouter Pos, PhD, Daniel Go, Etsuko Yasuda, Madalina Cercel, Susan E van Hal-van Veen, Esmay Frankin, Anikó Szabó, MD, Julien Villaudy, PhD, Pauline M van Helden, PhD, Hans van Eenennaam, PhD, Hergen Spits, PhD, Anita W Rijneveld, MD PhD, Mette D Hazenberg, MD PhD

Blood (2019) 134 (Supplement_1): 4461.

https://doi.org/10.1182/blood-2019-127894

Published: 2019

Journal Articles

Modulation of CD81 By Epigenetic Drug Combination Sensitizes Acute Lymphoblastic Leukemia Via Decreased BTK Signaling

Anthony Quagliano, BS, Anilkumar Gopalakrishnapillai, PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc

Blood (2019) 134 (Supplement_1): 2628.

https://doi.org/10.1182/blood-2019-129198

Published: 2019

Journal Articles

High frequency of inactivating tetraspanin C D37 mutations in diffuse large B-cell lymphoma at immune-privileged sites

Blood (2019) 134 (12): 946–950.

https://doi.org/10.1182/blood.2019001185

Published: 2019

Includes: Supplemental data

Journal Articles

Regulation of Homeostatic and Malignant B Cell Development By the Tetraspanin CD53

Zev J. Greenberg, BS, Darlene A. Monlish, PhD, Rachel L. Bartnett, Laura G. Schuettpelz, MD PhD

Blood (2018) 132 (Supplement 1): 3699.

https://doi.org/10.1182/blood-2018-99-111957

Published: 2018

Journal Articles

CD37 Expression in Acute Myeloid Leukemia Provides New Target for Directed Therapy

Karilyn Larkin, MD, Erin Guth, MS, Bonnie K. Harrington, DVM, Nicole Grieselhuber, MD PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 4056.

https://doi.org/10.1182/blood-2018-99-117262

Published: 2018

Journal Articles

The Impact of Immunotherapy on Tumor Evolution

Andrei Thomas-Tikhonenko, PhD

Blood (2018) 132 (Supplement 1): SCI-18.

https://doi.org/10.1182/blood-2018-99-109434

Published: 2018

Journal Articles

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Simone C. Oostindie, MSc, Hilma J. Van Der Horst, MSc, Marije B. Overdijk, PhD, Kristin Strumane, PhD, Sandra Verploegen, PhD, Margaret A. Lindorfer, PhD, Erica M. Cook, B.A., Martine E.D. Chamuleau, MD, Tuna Mutis, PhD, Janine Schuurman, PhD, A. Kate Sasser, PhD, Ronald P. Taylor, PhD, Paul W. H. I. Parren, PhD, Frank J. Beurskens, PhD, Esther C. W. Breij, PhD

Blood (2018) 132 (Supplement 1): 4170.

https://doi.org/10.1182/blood-2018-99-114723

Published: 2018

Journal Articles

Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples

Hilma J. Van Der Horst, MSc, Simone C. Oostindie, MSc, Saskia AGM Cillessen, MSc, Anne T Gelderloos, MSc, Marije B Overdijk, Martine E.D. Chamuleau, MD, Esther C. W. Breij, PhD, Tuna Mutis, PhD

Blood (2018) 132 (Supplement 1): 4179.

https://doi.org/10.1182/blood-2018-99-115886

Published: 2018

Journal Articles

Epigenetic Drug Combination Overcomes Bone Marrow Microenvironment-Induced Chemoprotection in Pediatric Acute Lymphoblastic Leukemia Via Modulation of CD81

Anthony Quagliano, BS, Anilkumar Gopalakrisnapillai, PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc

Blood (2018) 132 (Supplement 1): 3957.

https://doi.org/10.1182/blood-2018-99-120275

Published: 2018

Journal Articles

Targeting Aberrant Expression of CD81 Impacts Cell Adhesion and Migration, Drug Resistance and Prognosis of Acute Myeloid Leukemia

Fanny Gonzales, Thomas Boyer, Pauline Peyrouze, Soizic Guihard, Christophe Roumier, Céline Berthon, MD PhD, Claude Preudhomme, PharmD, PhD, Meyling Cheok, BSPharm, PhD

Blood (2017) 130 (Supplement 1): 2675.

https://doi.org/10.1182/blood.V130.Suppl_1.2675.2675

Published: 2017

Journal Articles

CD9 Blockade Effectively Suppresses Disease Progression of Pediatric B-Precursor Acute Lymphoblastic Leukemia and Enhances Chemosensitivity

Chi Zhang, MSc, Kam Tong Leung, PhD, Karen Li, PhD, Kathy Yuen Yee Chan, PhD, Alex Wing Kwan Leung, MRCPCH, John Tak Kit Cheung, BSc, Frankie Wai Tsoi Cheng, MD, Chi Kong Li, MD

Blood (2017) 130 (Supplement 1): 1327.

https://doi.org/10.1182/blood.V130.Suppl_1.1327.1327

Published: 2017

Journal Articles

Phosphoproteomic Landscaping Unveils Constitutive cKIT Activation in Human Erythroblasts from Polycythemia Vera (PV) Patients

Lilian Varricchio, PhD, Giulia Federici, PhD, Francesca Masiello, MS, Fabrizio Martelli, PhD, Mario Falchi, PhD, Orietta Picconi, Gabriella Girelli, MD, Agostino Tafuri, MD, Emanuel Petricoin III, PhD, Ann Zeuner, PhD, Anna Rita Migliaccio, PhD

Blood (2016) 128 (22): 399.

https://doi.org/10.1182/blood.V128.22.399.399

Published: 2016

Journal Articles

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma

Deborah M Stephens, DO, Kyle A. Beckwith, PhD, Priscilla Do, BS, Carolyn Cheney, BS, Xiaokui Mo, PhD MAS, Karilyn Larkin, MD, Jeffrey Jones, MD MPH, Farrukh T. Awan, Laura Grosmaire, PhD, Randy Jones, PhD, Julie DiPaolo, PhD, Stacey Tannheimer, Karl-Heinz Heider, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 2767.

https://doi.org/10.1182/blood.V128.22.2767.2767

Published: 2016

Journal Articles

Treating B Cell Lymphomas with Anti CD81 Antibodies

Felipe Vences-Catalan, PhD, Chiung-Chi Kuo, MsC, Ranjani Rajapaksa, PhD, Caroline Duault, PhD, Ronald Levy, MD, Shoshana Levy, PhD

Blood (2016) 128 (22): 4180.

https://doi.org/10.1182/blood.V128.22.4180.4180

Published: 2016

Journal Articles

The Tetraspanin CD9 Regulates Engraftment and Mobilization of Human CD34+ Hematopoietic Stem/Progenitor Cells and Modulates VLA-4 Activity

Kam Tong Leung, PhD, Karen Li, PhD, Yorky Tsin Sik Wong, BSc, Kathy Yuen Yee Chan, PhD, Xiao-Bing Zhang, PhD, Alex Wing Kwan Leung, MRCPCH, Tak Yeung Leung, MD, Kam Sze Tsang, PhD, Pak Cheung Ng, MD FRCPCH, Chi Kong Li, MD

Blood (2015) 126 (23): 1169.

https://doi.org/10.1182/blood.V126.23.1169.1169

Published: 2015

Journal Articles

The Role of Tetraspanin CD37 in B-Cell Malignancy

Kyle A. Beckwith, BS, Erich I. Williams, BS, Mark D. Wright, PhD, Annemiek B. van Spriel, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, PhD

Blood (2015) 126 (23): 1258.

https://doi.org/10.1182/blood.V126.23.1258.1258

Published: 2015

Journal Articles

Roles of Exosomes in the Hematopoietic Stem Cell-Supporting Capacity of Stromal Cells

Gregoire Stik, PhD, Simon Crequit, Jennifer Durant, Laurence Petit, Pierre Charbord, MD, Thierry Jaffredo, PhD, Charles Durand, PhD

Blood (2015) 126 (23): 1193.

https://doi.org/10.1182/blood.V126.23.1193.1193

Published: 2015

Journal Articles

A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results

Ahmed Sawas, MD, Kerry J. Savage, MDMSc, Raymond Perez, MD, Ranjana H Advani, MD, Anna Butturini, MD, Jacqueline Lackey, Fabio Trave, MD, Banmeet Anand, PhD, Yao Huang, Leonard Reyno, MD, Owen A. O'Connor, MD

Blood (2015) 126 (23): 3976.

https://doi.org/10.1182/blood.V126.23.3976.3976

Published: 2015

Journal Articles

The Tetraspanin CD81 Facilitates Tumor Metastasis By Modulating Immune Suppression

Felipe Vences Catalan, PhD, Ranjani Rajapaksa, PhD, Minu K. Srivastava, PhD, Aurelien Marabelle, MD PhD, Shoshana Levy, PhD

Blood (2014) 124 (21): 4136.

https://doi.org/10.1182/blood.V124.21.4136.4136

Published: 2014

NARROW

The Tetraspanin CD53 Regulates Early B Cell Development By Promoting IL-7R Signaling

AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia

Modulation of CD81 By Epigenetic Drug Combination Sensitizes Acute Lymphoblastic Leukemia Via Decreased BTK Signaling

High frequency of inactivating tetraspanin C D37 mutations in diffuse large B-cell lymphoma at immune-privileged sites

Regulation of Homeostatic and Malignant B Cell Development By the Tetraspanin CD53

CD37 Expression in Acute Myeloid Leukemia Provides New Target for Directed Therapy

The Impact of Immunotherapy on Tumor Evolution

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples

Epigenetic Drug Combination Overcomes Bone Marrow Microenvironment-Induced Chemoprotection in Pediatric Acute Lymphoblastic Leukemia Via Modulation of CD81

Targeting Aberrant Expression of CD81 Impacts Cell Adhesion and Migration, Drug Resistance and Prognosis of Acute Myeloid Leukemia

CD9 Blockade Effectively Suppresses Disease Progression of Pediatric B-Precursor Acute Lymphoblastic Leukemia and Enhances Chemosensitivity

Phosphoproteomic Landscaping Unveils Constitutive cKIT Activation in Human Erythroblasts from Polycythemia Vera (PV) Patients

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma

Treating B Cell Lymphomas with Anti CD81 Antibodies

The Tetraspanin CD9 Regulates Engraftment and Mobilization of Human CD34+ Hematopoietic Stem/Progenitor Cells and Modulates VLA-4 Activity

The Role of Tetraspanin CD37 in B-Cell Malignancy

Roles of Exosomes in the Hematopoietic Stem Cell-Supporting Capacity of Stromal Cells

A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results

The Tetraspanin CD81 Facilitates Tumor Metastasis By Modulating Immune Suppression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only